Nautilus Biotechnolgy, Inc. (NAUT)

Nautilus Biotechnology's stock price has experienced significant movement over the past six months. As of March 19, 2026, the share price was $2.76, a 175.53% increase from $1.00 on March 20, 2025, with a 52-week range between $0.62 and $4.31. Key events include the release of the Fourth Quarter and Fiscal Year 2025 financial results, participation in healthcare conferences, announcement of Baylor College of Medicine as the first Early Access Program customer, and an increase in the company's price target to $4.08.

Information directly detailing the demand seasonality for Nautilus Biotechnology's specific products and services is not explicitly available. However, the broader context suggests a growing market for proteomics, with analysts forecasting revenue growth for Nautilus, supported by increasing proteomics demand in areas like neurodegeneration and oncology. The global proteomics market is expected to grow at a 13% CAGR through 2030, indicating a generally positive long-term demand trend for the industry. The company is currently in a development stage, transitioning from early access customer engagements towards anticipated commercial revenue generation starting in 2027, which suggests that the primary focus is on market entry and adoption rather than established seasonal demand patterns.

Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome. The company operates in the Healthcare sector, specifically in the Biotechnology and Life Sciences Tools and Services industries, aiming to transform proteomics by democratizing access to the proteome. Their major product is the Nautilus Voyager Platform, an end-to-end solution for high-resolution, single-molecule protein analysis, including instruments, reagents, consumables, and software. The Voyager Platform is expected to launch in late 2026, with commercial revenue generation starting in 2027.

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, United States, with primary operations and focus within the United States. The company has research collaboration agreements with institutions such as Genentech, the Buck Institute, the Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation.

Nautilus Biotechnology has focused on establishing its presence and validating its technology within the proteomics field. The company aims to revolutionize biological research, drug identification and development, and human disease treatment through its large-scale, single-molecule proteomic analysis technology. Key factors influencing its reputation include collaborations with leading research centers and biotech partners, the launch of its Iterative Mapping Early Access Program, scientific presentations at conferences, and an ESG risk rating of 35.61, indicating a higher exposure to material ESG issues.

Nautilus Biotechnology, Inc. has a diverse ownership structure. Institutional investors hold a majority control with 47.09% ownership, while management insiders own a 33.82% stake, and other market participants hold 19.09%. Major institutional owners include AH Capital Management, L.L.C., Perceptive Advisors Llc, Cercano Management LLC, Madrona Venture Group, LLC, and Vanguard Group Inc. Key individual insider shareholders include Parag Mallick, Sujal M Patel, Anna Mowry, Matthew B. Murphy, and Kentaro Suzuki. Insiders have shown more buying than selling activity in the past three months, with $65,250.00 in company stock bought and no sales.